口服普萘洛尔联合复方倍他米松局部注射治疗婴幼儿血管瘤的疗效评价
Efficacy Evaluation of Oral Propranolol Combined with Compound Betamethasone Local Injection in the Treatment of Infantile Hemangioma
DOI: 10.12677/ACM.2020.1012460, PDF,   
作者: 耿 锐, 苏毅鹏, 李丹怡, 孙 晨, 陈振雨*:青岛大学附属医院美容整形外科,山东 青岛;耿向群:泰安市中心医院核医学科,山东 泰安;张 彬:青岛大学附属医院工会,山东 青岛
关键词: 普萘洛尔倍他米松婴幼儿血管瘤Propranolol Betamethasone Infantile Hemangioma
摘要: 目的:分析普萘洛尔联合倍他米松局部注射治疗婴幼儿血管瘤的临床疗效。方法:收集2018年5月至2020年6月就诊于青岛大学附属医院美容整形外科符合纳入标准的婴幼儿血管瘤患者61例,分组为单纯口服普萘洛尔组共19例,单纯局部注射复方倍他米松组共20例,口服普萘洛尔联合局部注射复方倍他米松治疗组共22例,术后随访观察6个月并评估临床疗效。结果:联合组的治愈率明显高于单纯注射复方倍他米松组和单纯口服普萘洛尔组,差异有统计学意义(P < 0.05)。复方倍他米松组与普萘洛尔组比较,两组治愈率无明显差异(P > 0.05)。联合组治疗时间明显短于单用复方倍他米松组和单用普萘洛尔组,差异有统计学意义(P < 0.05)。单用复方倍他米松组与单用普萘洛尔组患者的治疗时间无差别(P > 0.05)。所有口服普萘洛尔的患儿中有10例出现心率减慢,临床观察后恢复正常,未给予特殊处理。所有注射复方倍他米松的患儿中有6例出现术区肿胀,给予加压包扎后逐渐消退;有2例患儿在注射后出现烦躁。比较三组不良反应的发生率,差异无统计学意义(P > 0.05)。结论:口服普萘洛尔联合局部注射复方倍他米松治疗婴幼儿血管瘤疗效更佳。
Abstract: Objective: To analyze the clinical effect of propranolol combined with betamethasone local injection in the treatment of infantile hemangioma. Methods: A total of 61 infants and young children with hemangioma who met the inclusion criteria and visited the Department of Aesthetic and Plastic Surgery, Affiliated Hospital of Qingdao University from May 2018 to June 2020 were collected, there were 19 cases in propranolol group by oral administration alone, 20 cases in compound betamethasone group by local injection alone, and 22 cases in compound betamethasone treatment group by oral propranolol combined with local injection. The postoperative follow-up was observed for 6 months and the clinical efficacy was evaluated. Result: The cure rate of the combined group was significantly higher than that of the compound betamethasone injection group and the propranolol oral injection group, the difference was statistically significant (P < 0.05). There was no significant difference in cure rate between compound betamethasone group and propranolol group (P > 0.05). The duration of treatment in the combination group was significantly shorter than that in the compound betamethasone group and propranolol group alone, with statistically significant difference (P < 0.05). There was no difference in treatment time between compound betamethasone alone and propranolol alone (P > 0.05). Among all the children who took propranolol orally, 10 cases showed slow heart rate, which returned to normal after clinical observation without special treatment. Among all the children injected with compound betamethasone, 6 had swelling in the operative area, which gradually subsided after pressure dressing; two of the children developed dysphoria after injection. The incidence of adverse reactions in the three groups was not statistically significant (P > 0.05). Conclusion: Oral propranolol combined with local injection of compound betamethasone is more effective in the treatment of infantile hemangioma.
文章引用:耿锐, 耿向群, 苏毅鹏, 李丹怡, 孙晨, 张彬, 陈振雨. 口服普萘洛尔联合复方倍他米松局部注射治疗婴幼儿血管瘤的疗效评价[J]. 临床医学进展, 2020, 10(12): 3069-3075. https://doi.org/10.12677/ACM.2020.1012460

参考文献

[1] Hochman, M. (2014) Infantile Hemangiomas: Current Management. Facial Plastic Surgery Clinics of North America, 22, 509-521. [Google Scholar] [CrossRef] [PubMed]
[2] Kilcline, C. and Frieden, I.J. (2008) Infantile Hemangiomas: How Common Are They? A Systematic Review of the Medical Literature. Pediatric Dermatology, 25, 168-173. [Google Scholar] [CrossRef] [PubMed]
[3] 中华医学会整形外科分会血管瘤和脉管畸形学组. 血管瘤和脉管畸形的诊断及治疗指南(2019版) [J]. 组织工程与重建外科杂志, 2019, 15(5): 277-317.
[4] Hoeger, P.H., Harper, J.I., Baselga, E., et al. (2015) Treatment of Infantile Haemangiomas: Recommendations of a European Expert Group. European Journal of Pediatrics, 174, 855-865. [Google Scholar] [CrossRef] [PubMed]
[5] 杨浩, 舒强, 郭晓东. 婴幼儿血管瘤的治疗进展[J]. 临床小儿外科杂志, 2019, 18(8): 640-645.
[6] Léauté-Labrèze, C., de la Roque, E.D., Hubiche, T. and Boralevi, F. (2008) Propranolol for Severe Hemangiomas of Infancy. New England Journal of Medicine, 358, 2649-2651. [Google Scholar] [CrossRef
[7] Zarem, H.A. and Edgerton, M.T. (1967) Induced Resolution of Cavernous Hemangiomas Following Prednisolone Therapy. Plastic & Reconstructive Surgery, 39, 76-83. [Google Scholar] [CrossRef] [PubMed]
[8] Sloan, G.M., Reinisch, J.F., Nichter, L.S., et al. (1989) Intralesional Corticosteroid Therapy for Infantile Hemangiomas. Plastic & Reconstructive Surgery, 83, 459-467. [Google Scholar] [CrossRef] [PubMed]
[9] 张世仁, 仇雅璟, 蔡宜佐, 等. 婴幼儿血管瘤瘤体内注射药物治疗研究进展[J]. 中华整形外科杂志, 2019, 35(2): 201-204.
[10] Achauer, B., Chang, C.-J. and Vander Kam, V. (1997) Management of Hemangioma of Infancy: Review of 245 Patients. Plastic & Reconstructive Surgery, 99, 1301-1308. [Google Scholar] [CrossRef] [PubMed]
[11] Mulliken, J.B. and Glowacki, J. (1982) Hemangiomas and Vascular Malformations in Infants and Children. Plastic & Reconstructive Surgery, 69, 421-422. [Google Scholar] [CrossRef
[12] Laken, P.A. (2016) Infantile Hemangiomas: Pathogenesis and Review of Propranolol Use. Advances in Neonatal Care, 16, 135-142. [Google Scholar] [CrossRef
[13] Smith, C.J.F., Friedlander, S.F., Guma, M., et al. (2017) Infantile Hemangiomas: An Updated Review on Risk Factors, Pathogenesis, and Treatment. Birth Defects Research, 109, No. 11. [Google Scholar] [CrossRef] [PubMed]
[14] Léauté-Labrèze, C., Harper, J.I. and Hoeger, P.H. (2017) Infantile Haemangioma. Lancet, 390, 85-94. [Google Scholar] [CrossRef
[15] Bauland, C.G., Lüning, T.H., Smit, J.M., et al. (2011) Untreated Hemangiomas: Growth Pattern and Residual Lesions. Plastic and Reconstructive Surgery, 127, 1643-1648. [Google Scholar] [CrossRef
[16] Couto, R.A., Maclellan, R.A., Zurakowski, D., et al. (2012) Infantile Hemangioma: Clinical Assessment of the Involuting Phase and Implications for Management. Plastic and Reconstructive Surgery, 130, 619-624. [Google Scholar] [CrossRef
[17] Luu, M. and Frieden, I.J. (2013) Haemangioma: Clinical Course, Complications and Management. British Journal of Dermatology, 169, 20-30. [Google Scholar] [CrossRef] [PubMed]
[18] Zhang, L., Wu, H.W., Yuan, W.E. and Zheng, J. (2017) Propranolol Therapy for Infantile Hemangioma: Our Experience. Drug Design, Development and Therapy, 11, 1401-1408. [Google Scholar] [CrossRef
[19] 郑家伟. 婴幼儿血管瘤“等待观察”的治疗策略应予改变[J]. 中国口腔颌面外科杂志, 2012(2): 163-164.
[20] Storch, C.H. and Hoeger, P.H. (2010) Propranolol for Infantile Haemangiomas: Insights into the Molecular Mechanisms of Action. British Journal of Dermatology, 163, 269-274. [Google Scholar] [CrossRef] [PubMed]
[21] None (2008) More on Propranolol for Hemangiomas of Infancy. New England Journal of Medicine, 359, 2846-2847. [Google Scholar] [CrossRef
[22] 中华医学会整形外科分会血管瘤和脉管畸形学组. 血管瘤和脉管畸形诊断和治疗指南(2016版) [J]. 组织工程与重建外科杂志, 2016, 12(2): 63-93.
[23] Kushner, B.J. (1982) Intralesional Corticosteroid Injection for Infantile Adnexal Hemangioma. American Journal of Ophthalmology, 93, 496-506. [Google Scholar] [CrossRef] [PubMed]
[24] 位永娟, 周昉, 等. 糖皮质激素对血管瘤治疗机制的研究进展[J]. 中华妇幼临床医学杂志(电子版), 2008, 4(2): 131-138.
[25] 刘潜, 李静, 周德凯, 等. 糖皮质激素瘤内注射治疗婴幼儿血管瘤机理的研究[J]. 医学争鸣, 2007, 28(13): 1199-1201.